Are we dependent upon coffee and caffeine? A review on human and animal data

Neuroscience and Biobehavioral Reviews

Volumn 23, Issue 4, 1999, Pages 563-576

  Nehlig, Astrid ^a  

^a INSERM   (France)

Author keywords

Caffeine; Dependence; Discrimination; Drugs of abuse; Tolerance; Withdrawal

Indexed keywords

CAFFEINE;

ABSORPTION; BRAIN FUNCTION; COFFEE; DISCRIMINATION LEARNING; DRUG DEPENDENCE; DRUG MECHANISM; DRUG TOLERANCE; FOOD INTAKE; HUMAN; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; REINFORCEMENT; REVIEW; WITHDRAWAL SYNDROME;

ANIMALS; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; COFFEE; HUMANS; SUBSTANCE-RELATED DISORDERS;

EID: 0033011807     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(98)00050-5     Document Type: Review

References (200)

1. 6-(phenylisopropyl)-adenosine (PIA) in mice. Life Sci. 38:1986;577-588.
2. Aldridge A., Aranda J.V., Neims A.H. Caffeine metabolism in the newborn. Clin Pharmacol Ther. 25:1979;447-453.
3. Aldridge A., Bailey J., Neims A.H. The disposition of caffeine during and after pregnancy. Semin Perinatol. 5:1981;310-314.
4. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. Revised 3rd ed. Washington DC: American Psychiatric Association, 1987.
5. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 4th ed. Washington DC: American Psychiatric Association, 1992.
6. Ammon H.P.T., Bieck P.R., Mandalaz D., Verspohl E.J. Adaptation of blood pressure to continuous heavy coffee drinking in young volunteers. A double-blind crossover study. Br J Clin Pharmacol. 15:1983;701-706.
7. Aranda J.V., Collinge J.M., Zinman R., Watters G. Maturation of caffeine elimination in infancy. Arch Dis Child. 54:1979;946-949.
8. Aranda J.V., Gorman W., Bergsteinsson H., Gunn T. Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. J Pediatr. 90:1977;467-472.
9. Aranda J.V., MacLeod S.M., Renton K.W., Eade N.R. Hepatic microsomal drug oxidation and electron transport in newborn infants. J Pediatr. 85:1974;534-542.
10. 14C)caffeine metabolites in rat's urine by chromatographic separations. Biochem Med. 16:1976;67-76.
11. 14C)caffeine in rats, mice, and chinese hamsters. Drug Metab Dispos. 13:1985;471-478.
12. Arnaud M.J. The pharmacology of caffeine. Progr Drug Res. 31:1987;273-313.
13. Arnaud MJ. Metabolism of caffeine. In: Garattini S, editor. Caffeine, coffee and health. New York: Raven Press, 1993:43-95.
14. Arnaud MJ, Welsch C. Theophylline and caffeine metabolism in man. In: Reitbrock N, Woodcock BG, Staib AH, editors. Theophylline and other methylxanthines. Friedr. Zurich: Vieweg, 1982:135-148.
15. Atkinson J., Ensslen M. Self-administration of caffeine by the rat. Arzneimittelforschung. 26:1976;2059-2061.
16. Barone JJ, Roberts H. Human consumption of caffeine. In: Dews PB, editor. Caffeine: perspectives from recent research. Heidelberg: Springer, 1984:59-73.
17. Barone J.J., Roberts H.R. Caffeine consumption. Food Chem Toxicol. 34:1996;119-126.
18. Bättig K. The physiological effects of coffee consumption. In: Clifford MN, Wilson KC. editors. Coffee: botany, biochemistry and production of beans and beverages. Westport, CT: AVI, 1985:394-439.
19. Benowitz N.L. Clinical pharmacology of caffeine. Ann Rev Med. 41:1990;277-288.
20. Bickel W.K., Degrandpre R.J., Higgins S.T. The behavioral economics of concurrent drug reinforcers: a review and reanalysis of drug self-administration research. Psychopharmacology. 118:1995;250-259.
21. Blanchard J., Sawers S.J.A. The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol. 24:1983;93-98.
22. Blanchard J., Sawers S.J.A. Comparative pharmacokinetics of caffeine in young and elderly men. J Pharmacokin Biopharmaceut. 11:1983;109-126.
23. Bonati M., Latini R., Galetti F., Young J.F., Tognoni G., Garattini S. Caffeine disposition after oral doses. Clin Pharmacol Ther. 32:1982;98-106.
24. Bonati M., Latini R., Tognoni G., Young J.F., Garattini S. Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat, and mouse. Drug Metab Rev. 15:1984;1355-1383.
25. Bonnet M.H., Arand D.L. Caffeine use as a model of acute and chronic insomnia. Sleep. 15:1992;526-536.
26. Booth D.A., French J.A., Wainwright C.J., Gatherer A.J.H. Personal benefits from post-ingestional actions of dietary constituents. Proc Nutr Soc. 51:1992;335-341.
27. Brauer L.H., Buican B., de Wit H. Effects of caffeine deprivation on taste and mood. Behav Pharmacol. 5:1994;111-118.
28. Brazier J.L., Ritter J., Berland M., Khenfer D., Faucon G. Pharmacokinetics of caffeine during and after pregnancy. Dev Pharmacol Ther. 6:1983;315-322.
29. Breslau N., Kilbey M.M., Andreski P. Nicotine dependence and major depression: new evidence from a prospective investigation. Arch Gen Psychiatry. 50:1993;31-35.
30. Brovsic G.M., Rowe M.M. Methylxanthines, adenosine, and human taste responsivity. Physiol Behav. 52:1992;559-563.
31. Carney J.M. Effects of caffeine, theophylline and theobromine on scheduled controlled responding in rats. Brit J Pharmacol. 75:1982;451-454.
32. Carrier O., Pons G., Rey E., Richard M.O., Moran C., Badoual J., Olive G. Maturation of caffeine metabolic pathways in infancy. Clin Pharmacol Ther. 44:1988;145-151.
33. Carroll M.E., Hagen E.W., Asencio M., Brauer L.H. Behavioral dependence on caffeine and phencyclidine in rhesus monkeys: interactive effects. Pharmacol Biochem Behav. 31:1989;927-932.
34. Chait L.D., Uhlenhuth E.H., Johanson C.E. Reinforcing and subjective effects of several anorectics in normal human volunteers. J Pharmacol Exp Ther. 242:1987;777-783.
35. Chou D.T., Khan S., Forde J., Hirsh K. Caffeine tolerance: behavioral, electrophysiological and neurochemical evidence. Life Sci. 36:1985;2347-2358.
36. Clubley M., Bye C.E., Henson T.A., Peck A.W., Riddington C.J. Effects of caffeine and cyclizine alone and in combination on human performance, subjective effects and EEG activity. Brit J Clin Pharmacol. 7:1979;157-163.
37. Collins R.J., Weeks J.R., Cooper M.M., Good P.I., Russell R.R. Prediction of abuse liability of drugs using IV self-administration by rats. Psychopharmacology. 82:1984;6-13.
38. Colton T., Gosselin R.E., Smith R.P. The tolerance of coffee drinkers to caffeine. Clin Pharmacol Ther. 9:1968;31-39.
39. Couturier E.G.M., Laman D.M., van Duijn M.A.J., van Duijn H. Influence of caffeine and caffeine withdrawal on headache and cerebral blood flow velocities. Cephalalgia. 17:1997;188-190.
40. Curatolo P.W., Robertson D. The health consequences of caffeine. Ann Int Med. 98:1983;641-653.
41. Daly JW. Mechanism of action of caffeine. In: Garattini S, editor. Caffeine, coffee and health. New York: Raven Press, 1993:97-150.
42. D'Amicis A, Viani R. The consumption of coffee. In: Garattini S, editor. Caffeine, coffee and health. New York: Raven Press, 1993:1-16.
43. 1 receptors and their coupling to G proteins in the rat brain. Neuroscience. 40:1991;841-851.
44. Debry G. Coffee and health. Paris: Libbey, 1994.
45. Denaro C.P., Brown C.R., Jacob P. III, Benowitz N.L. Effects of caffeine with repeated dosing. Eur J Clin Pharmacol. 40:1991;273-278.
46. Denaro C.P., Brown C.R., Wilson M., Jacob P. III, Benowitz N.L. Dose-dependency of caffeine metabolism. Clin Pharmacol Ther. 31:1990;358-369.
47. Deneau G., Yanagita T., Seevers M.H. Self-administration of psychoactive substances in the monkey: a measure of psychological dependence. Psychopharmacologia. 16:1969;30-48.
48. Dreisbach R.H., Pfeiffer C. Caffeine withdrawal headache. J Lab Clin Med. 28:1943;1212-1219.
49. Dworkin S.I., Vrana S.L., Broadbent J., Robinson J.H. Comparing the reinforcing effects of nicotine, caffeine, methylphenidate and caffeine. Med Chem Res. 2:1993;593-602.
50. Eddy N.B., Downs A.W. Tolerance and cross-tolerance in the human subject to the diuretic effect of caffeine, theobromine and theophylline. J Pharmacol Exp Ther. 33:1928;167-174.
51. Ellison C.R., Singer M.R., Moore L.L., Nguyen U.S.D.T., Garrahie E., Maror J.K. Current caffeine intake in young children: amount and sources. J Amer Dietetic Assoc. 95:1995;802-804.
52. Evans S.M., Critchfield T.S., Griffiths R.R. Caffeine reinforcement demonstrated in a majority of moderate caffeine users. Behav Pharmacol. 5:1994;231-238.
53. Evans S.M., Griffiths R.R. Caffeine tolerance and choice in humans. Psychopharmacology. 108:1992;51-59.
54. Fastbom J., Pazos A., Ungerstedt U., Rudolphi K., Fredholm B.B. Protective effect of adenosine and a novel xanthine derivative propentofylline on the cell damage after bilateral carotid occlusion in the gerbil hippocampus. Neuroscience. 22:1990;813-826.
55. Fennelly M., Galletly D.C., Purdie G.I. Is caffeine withdrawal the mechanism of postoperative headaches? Anesth Analg. 72:1991;449-453.
56. Ferré S., Fuxe K., von Euler G., Johansson B., Fredholm B.B. Adenosine-dopamine interactions in the brain. Neuroscience. 51:1992;501-512.
57. Ferré S., von Euler G., Johansson B., Fredholm B.B., Fuxe K. Stimulation of high-affinity adenosine A-2 receptors decreases the affinity of dopamine D-2 receptors in rat striatal membranes. Proc Natl Acad Sci USA. 88:1991;7237-7241.
58. Fink J.S., Weaver D.R., Rivkees S.A., Peterfreund R.A., Pollack A.E., Adler E.M., Reppert S.M. Molecular cloning of the rat A2 adenosine receptor: selective expression with D2 dopamine receptors in rat striatum. Mol Brain Res. 14:1992;186-195.
59. Finn I.B., Holtzman S.G. Tolerance to caffeine-induced stimulation of locomotor activity in rats. J Pharmacol Exp Ther. 238:1986;542-546.
60. Finn I.B., Holtzman S.G. Pharmacological specificity of tolerance to caffeine-induced stimulation of locomotor activity. Psychopharmacology. 93:1987;428-434.
61. Finn I.B., Holtzman S.G. Tolerance and cross-tolerance to theophylline-induced stimulation of locomotor activity in rats. Pharmacol Biochem Behav. 35:1988;477-479.
62. Fredholm B.B. Are methylxanthine effects due to antagonism of endogenous adenosine? Trends Pharmacol Sci. 1:1980;129-132.
63. Fredholm B.B. Adenosine, adenosine receptors and the actions of caffeine. Pharmacol Toxicol. 76:1995;93-101.
64. French J.A., Wainwright C.J., Booth D.A. Caffeine and mood: individual differences in low-dose caffeine sensitivity. Appetite. 22:1994;277-279.
65. Garrett B.E., Griffiths R.R. The role of dopamine in the behavioral effects of caffeine in animals and humans. Pharmacol Biochem Behav. 57:1997;533-541.
66. 2 receptor agonists but not to their synergistic interaction. Eur J Pharmacol. 262:1994;65-75.
67. Garrett B.E., Holtzman S.G. Does adenosine receptor blockade mediate caffeine-induced rotational behavior? J Pharmacol Exp Ther. 274:1995;207-214.
68. 1 receptor number. Brain Res. 612:1993;271-277.
69. Gilbert RM. Caffeine as a drug of abuse. In: Gibbins RJ, Israel Y, Kalant H, Popham RE, Schmidt W, Smart RG, editors. Research advances in alcohol and drug problems, vol. 3. New York: Wiley, 1976:49-77.
70. Gilbert RM. Caffeine consumption. In: Spiller GA, editor. The methylxanthine beverages and foods: chemistry, consumption, and health effects. New York: Liss, 1984:185-213.
71. Gilliland K., Bullock W. Caffeine: a potential drug of abuse. Adv Alcohol Subst Abuse. 3:1984;53-73.
72. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 379:1996;606-612.
73. Goldstein A., Kaizer S. Psychotropic effects of caffeine in man. III. A questionnaire survey of coffee drinking and its effects in a group of housewifes. Clin Pharmacol Ther. 10:1969;477-488.
74. Goldstein A., Kaizer S., Whitby O. Psychotropic effects of caffeine in man. IV. Quantitative and qualitative differences associated with habituation to coffee. Clin Pharmacol Ther. 10:1969;489-497.
75. Goldstein A., Kalant H. Drug policy: striking the right balance. Science. 249:1990;1513-1521.
76. Goldstein A., Warren R., Kaizer S. Psychotropic effects of caffeine in man. I. Interindividual differences in sensitivity to caffeine-induced wakefulness. J Pharmacol Exp Ther. 149:1965;156-159.
77. 3H ) cyclohexyladenosine J Neurosci. 2:1982;1230-1241.
78. Griffiths R.R., Bigelow G.E., Liebson I.A. Human coffee drinking: reinforcing and physical dependence producing effects of caffeine. J Pharmacol Exp Ther. 239:1986;416-425.
79. Griffiths R.R., Bigelow G.E., Liebson I.A., O'Keffe M., O'Leary D., Russ N. Human coffee drinking: manipulation of concentration and caffeine dose. J Exp Anal Behav. 45:1986;133-148.
80. Griffiths R.R., Bigelow G.E., Liebson I.A. Reinforcing effects of caffeine in coffee and capsules. J Exp Anal Behav. 52:1989;127-140.
81. Griffiths RR, Brady JV, Bradford LD. Predicting the abuse liability of drugs with animal drug self-administration procedures: psychomotor stimulants and hallucinogens. In: Thompson D, Dews PB, editors. Advances in behavioral pharmacology, vol. 2. New York: Academic Press, 1979:163-208.
82. Griffiths R.R., Evans S.M., Heishman S.J., Preston K.L., Sannerud C.A., Wolf B., Woodson P.P. Low-dose caffeine discrimination in humans. J Pharmacol Exp Ther. 252:1990;970-978.
83. Griffiths R.R., Evans S.M., Heishman S.J., Preston K.L., Sannerud C.A., Wolf B., Woodson P.P. Low-dose caffeine physical dependence in humans. J Pharmacol Exp Ther. 255:1990;1123-1132.
84. Griffiths RR, Mumford GK. Caffeine - a drug of abuse? In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995:1699-1713.
85. Griffiths RR, Mumford GK. Caffeine reinforcement, discrimination, tolerance and physical dependence in laboratory animals and humans. In: Schuster CR, Kuhar MJ, editors. Handbook of experimental pharmacology, vol. 118. Heidelberg: Springer, 1996:315-341.
86. Griffiths R.R., Woodson P.P. Reinforcing effects of caffeine in humans. J Pharmacol Exp Ther. 246:1988;21-28.
87. Griffiths R.R., Woodson P.P. Reinforcing properties of caffeine: studies in humans and laboratory animals. Pharmacol Biochem Behav. 29:1988;419-427.
88. Griffiths R.R., Woodson P.P. Caffeine physical dependence: a review of human and laboratory animal studies. Psychopharmacology. 94:1988;437-451.
89. Hampl K.F., Schneider M.C., Ruttimann U., Ummenhofer U., Drewe J. Perioperative administration of caffeine tablets for prevention of postoperative headaches. Can J Anaesth. 42:1995;789-792.
90. Hart P., Farrell G.C., Cooksley W.G.E., Powell I.W. Enhanced drug metabolism in cigarette smokers. Brit Med J. 2:1976;147-149.
91. Heimer L., Zahm D.S., Churchill L., Kalivas P.W., Wohltmann C. Specificity in the projection patterns of accumbal core and shell in the rat. Neuroscience. 41:1991;89-125.
92. Heishman S.J., Henningfield J.E. Stimulus functions of caffeine in humans: relation to dependence potential. Neurosci Biobehav Rev. 16:1992;273-287.
93. Heishman S.J., Henningfield J.E. Is caffeine a drug of dependence? Criteria and comparisons. Pharmacopsychoecologia. 7:1994;127-136.
94. Hirsch K. Central nervous system pharmacology of the dietary methylxanthines. In: Spiller GA, editor. The methylxanthine beverages and food: chemistry, consumption, and health effects. New York: Liss, 1984:235-301.
95. Hirsch K.R., Forde J., Chou D.T. Demonstration of caffeine tolerance in reticular formation neurons. Fed Proc. 42:1983;882.
96. Höfer L., Bättig K. Cardiovascular, behavioral, and subjective effects of caffeine under field conditions. Pharmacol Biochem Behav. 48:1994;899-908.
97. Höfer L., Bättig K. Psychophysiological effects of switching to caffeine tablets or decaffeinated coffee under field conditions. Pharmacopsychoecologia. 7:1994;169-177.
98. Holtzman S.G. Complete, reversible, drug-specific tolerance to stimulation of locomotor activity by caffeine. Life Sci. 33:1983;779-787.
99. Holtzman S.G. Caffeine as a model drug of abuse. Trends Pharmacol Sci. 11:1990;355-356.
100. Holtzman S.G., Finn I.B. Tolerance to the behavioral effects of caffeine in rats. Pharmacol Biochem Behav. 29:1988;411-418.
101. Holtzman S.G., Mante S., Minneman K.P. Role of adenosine receptors in caffeine tolerance. J Pharmacol Exp Ther. 256:1991;62-68.
102. Howell L.L. Comparative effects of caffeine and selective phosphodiesterase inhibitors on respiration and behavior in rhesus monkeys. J Pharmacol Exp Ther. 266:1993;894-903.
103. Hughes J.R., Higgins S.T., Bickel W.K., Hunt W.K., Fenwick J.W., Gulliver S.B., Mireault G.C. Caffeine self-administration, withdrawal, and adverse effects among coffee drinkers. Arch Gen Psychiatry. 48:1991;611-617.
104. Hughes J.R., Hunt W.K., Higgins S.T., Bickel W.K., Fenwick J.W., Pepper S.L. Effect of dose on the ability of caffeine to serve as a reinforcer in humans. Behav Pharmacol. 3:1992;218-221.
105. Hughes J.R., Oliveto A.H., Bickel W.K., Higgins S.T., Badger G.J. Caffeine self-administration and withdrawal: incidence, individual differences and interrelationships. Drug Alcohol Depend. 32:1993;239-246.
106. Hughes JR, Oliveto AH, Helzer JE, Bickel WK, Higgins ST. Indications of caffeine dependence in a population-based sample. In: Harris LS, editor. Problems of drug dependence 1992. NIDA research monographs no. 132, NIH publication no. 93-3505. Washington DC: US Government Printing Office, 1993:194.
107. Hughes J.R., Oliveto A.H., Helzer J.E., Higgins S.T., Bickel W.K. Should caffeine abuse, dependence, or withdrawal be added to DSM-IV and ICD-10? Amer J Psychiatry. 149:1992;33-40.
108. James JE. Caffeine and health. London: Academic Press, 1991.
109. James J.E., Stirling K.P. Caffeine: a survey of some of the known and suspected deleterious effects of habitual use. Brit J Addict. 78:1983;251-258.
110. 3H )CGS 21680 Eur J Pharmacol. 168:1989;243-246.
111. Joeres R., Klinker H., Heusler H., Epping J., Zilly W., Richter E. Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis. Hepatology. 8:1988;575-579.
112. Johanson C.E., Kilgore K., Uhlenhuth E.H. Assessment of dependence potential of drugs in humans using multiple indices. Psychopharmacology. 81:1983;144-149.
113. Johansson B., Lindström K., Fredholm B.B. Differences in the regional and cellular localization of c-fos messenger RNA induced by amphetamine, cocaine and caffeine in the rat. Neuroscience. 59:1994;837-849.
114. Johnson S.W., North R.A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci. 12:1992;483-488.
115. Katz J.L., Goldberg S.R. Psychomotor stimulant effects of caffeine alone and in combination with an adenosine analog in the squirrel monkey. J Pharmacol Exp Ther. 242:1987;179-187.
116. Kendler K.S., Neale M.C., MacLean C.J., Heath A.C., Eaves L.J., Kessler R.C. Smoking and major depression: a causal analysis. Arch Gen Psychiatry. 50:1993;36-43.
117. Kessler R.C., McGonagh K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., Wittchen H.U. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry. 51:1994;8-19.
118. Knutti R., Rothweiler H., Schlatter C. Effect of pregnancy on the pharmacokinetics of caffeine. Eur J Clin Pharmacol. 21:1981;121-126.
119. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci. 13:1992;177-184.
120. Kosman M.E., Unna K.R. Effects of chronic administration of the amphetamines and other stimulants on behavior. Clin Pharmacol Ther. 9:1968;240-254.
121. Kozlowski L.T. Effect of caffeine on coffee drinking. Nature. 264:1976;354-355.
122. Kozlowski L.T., Henningfield J.E., Keenan R.M., Lei H., Leigh G., Jelinek L.C., Pope M.A., Haertzen C.A. Patterns of alcohol, cigarette, and caffeine and other drug use in two abusing populations. J Subst Abuse Treat. 10:1993;171-179.
123. Kuznicki J.T., Turner L.S. The effects of caffeine on caffeine users and non-users. Physiol Behav. 37:1986;397-408.
124. Lane J.D. Effects of brief caffeinated-beverage deprivation on mood, symptoms, and psychomotor performance. Pharmacol Biochem Behav. 58:1997;203-208.
125. Le Guennec C., Billon B. Delay in caffeine elimination in breast-fed infants. Pediatrics. 79:1987;264-268.
126. Levy M., Zylber-Katz E. Caffeine metabolism and coffee attributed sleep disturbances. Clin Pharmacol Ther. 33:1983;770-775.
127. Liebermann H.R., Wurtmann R.J., Emde G.G., Coviella I.L.G. The effects of caffeine and aspirin on mood and performance. J Clin Psychopharmacol. 7:1987;315-320.
128. Liebermann H.R., Wurtmann R.J., Emde G.G., Roberts C., Coviella I.L.G. The effects of low doses of caffeine on human performance and mood. Psychopharmacology. 92:1987;308-312.
129. London E.D., Connolly R.J., Szikszay M., Wamsley J.K., Dam M. Effects of nicotine on local cerebral glucose utilization in the rat. J Neurosci. 8:1988;3920-3928.
130. Lorist M.M., Snel J., Kok A. Influence of caffeine on information processing stages in well rested and fatigued subjects. Psychopharmacology. 113:1994;411-421.
131. Maldonado R., Salardi A., Valverde O., Samad T.A., Roques B.P., Borelli E. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature. 388:1997;586-589.
132. Marks V., Kelly J.F. Absorption of caffeine from tea, coffee and coca cola. Lancet. 1:1973;827.
133. Matthew R.J., Wilson W.H. Caffeine consumption, withdrawal and cerebral blood flow. Headache. 25:1985;305-309.
134. McGowan J.D., Altman R.E., Kanto W.P. Neonatal withdrawal symptoms after chronic maternal ingestion of caffeine. South Med J. 81:1988;1092-1094.
135. Mela D.J., Mattes R.D., Tanimura S., Garcia-Medina M.R. Relationships between ingestion and gustatory perception of caffeine. Pharmacol Biochem Behav. 43:1992;513-521.
136. Mumford G.K., Neill D.B., Holtzman S.G. Caffeine elevates reinforcement threshold for electrical brain stimulation: tolerance and withdrawal changes. Brain Res. 459:1988;163-167.
137. Murphy T.L., McIvor G., Yap A., Cooksley W.G.F., Hallyday J.W., Powell I.W. The effect of smoking on caffeine elimination: implication for its use as a semiquantitative test of liver function. Clin Exp Pharmacol Physiol. 15:1988;9-13.
138. Nehlig A., Daval J.L., Boyet S., Vert P. Comparative effects of acute and chronic administration of caffeine on local cerebral glucose utilization in the conscious rat. Eur J Pharmacol. 129:1986;93-103.
139. Nehlig A., Daval J.L., Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Rev. 17:1992;139-170.
140. Nehlig A, Debry G. Effects of coffee on the central nervous system. In: Debry G, editor. Coffee and health. London: Libbey, 1994:157-249.
141. Nehlig A., Lucignani G., Kadekaro M., Porrino L.J., Sokoloff L. Effects of acute administration of caffeine on local cerebral glucose utilization in the rat. Eur J Pharmacol. 101:1984;91-100.
142. Nemeth-Coslett R., Henningfield J.E., O'Keefe M.K., Griffiths R.R. Nicotine gum: dose-related effects on cigarette smoking and subjective ratings. Psychopharmacology. 92:1987;424-430.
143. Newland M.C., Brown K. Oral caffeine consumption by rats: the role of flavor history, concentration, concurrent food, and an adenosine agonist. Pharmacol Biochem Behav. 42:1992;651-659.
144. Nikolajsen L., Larsen K.M., Kierkegaard O. Effect of previous frequency of headache, duration of fasting and caffeine abstinence on perioperative headache. Brit J Anaesth. 72:1994;295-297.
145. Okada M., Kiryu K., Kawata Y., Mizuno K., Wada K., Tasaki H., Kaneko S. Determination of the effects of caffeine and carbamazepine on striatal dopamine release by in vivo microdialysis. Eur J Pharmacol. 321:1997;181-188.
146. Okada M., Mizuno K., Kaneko S. Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci Lett. 212:1996;53-56.
147. Oliveto A.H., Hughes J.R., Higgins S.T., Bickel W.K., Pepper S.L., Shea P.J., Fenwick J.W. Forced-choice versus free-choice procedures: caffeine self-administration in humans. Psychopharmacology. 109:1992;85-91.
148. Oliveto AH, Hughes JR, Pepper SL, Bickel WK, Higgins ST. Low doses of caffeine can serve as reinforcers in humans. In: Harris LS, editor. Problems of drug dependence, 1990, NIDA research monograph no. 105. Washington, DC: US Government Printing Office, 1991:442.
149. Ongini E., Fredholm B.B. Pharmacology of adenosine A2 receptors. Trends Pharmacol Sci. 17:1996;364-372.
150. Orzi F., Morelli M., Fieschi C., Pontieri F.E. Metabolic mapping of the pharmacological and toxicological effects of dopaminergic drugs in experimental animals. Cerebrovasc Brain Metab Rev. 5:1993;95-121.
151. Pagliusi S.R., Tessari M., DeVevey S., Chiamulera C., Pich E.M. The reinforcing properties of nicotine are associated with a specific patterning of c-fos expression in the rat brain. Eur J Neurosci. 8:1996;2247-2256.
152. Paire M., van Lieferinghen P., Desvignes V., Dubray C., Raynaud E.J., Lavarenne J. Cinétique de la caféine au cours des premiers mois de la vie et implications pratiques. Sem Hôp Paris. 64:1988;1813-1817.
153. 3H )-CGS 21680 as a ligand Naunyn-Schmiedeberg's Arch Pharmacol. 342:1990;85-89.
154. Parsons W.D., Neims A.H. Prolonged half-life of caffeine in healthy term newborn infants. J Pediatr. 98:1981;640-641.
155. Patwardhan R.V., Desmond P.V., Johnson R.F., Schenker S. Impaired elimination of caffeine by oral contraceptive steroids. J Lab Clin Med. 95:1980;603-608.
156. Pearlman S.A., Duran C., Wood M.A., Maisels M.J., Berlin C.M. Caffeine pharmacokinetics in preterm infants older than 2 weeks. Dev Pharmacol Ther. 12:1989;65-69.
157. Pickworth W.B., Bunker E.B., Henningfield H.E. Transdermal nicotine: reduction of smoking with minimal abuse liability. Psychopharmacology. 115:1994;9-14.
158. 2 dopamine-dependent activation of fos in the striatopallidal pathway. Neuroscience. 68:1995;721-728.
159. Pontieri F.E., Tanda G., Dichiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the 'shell' as compared with the 'core' of the rat nucleus accumbens. Proc Natl Acad Sci USA. 92:1995;12304-12308.
160. Pontieri F.E., Tanda G., Orzi F., Dichiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature. 382:1996;255-257.
161. Porrino L.J. Functional consequences of acute cocaine treatment depend on route of administration. Psychopharmacology. 112:1993;343-351.
162. Porrino L.J., Domer F.R., Crane A.M., Sokoloff L. Selective alterations in cerebral metabolism within the mesocorticolimbic dopaminergic system produced by acute cocaine administration in rats. Neuropsychopharmacology. 1:1988;109-118.
163. Porrino L.J., Lucignani G., Dow-Edwards D., Sokoloff L. Correlation of dose-dependent effects of acute amphetamine administration on behavior and local cerebral metabolism in rats. Brain Res. 307:1984;311-320.
164. Richardson N.J., Rogers P.J., Elliman N.A., O'Dell R.J. Mood and performance effects of caffeine in relation to acute and chronic caffeine deprivation. Pharmacol Biochem Behav. 52:1995;313-320.
165. Robertson D., Wade D., Workman R., Woosley R.L., Oates J.A. Tolerance to the humoral and hemodynamic effects of caffeine in man. J Clin Invest. 67:1981;1111-1117.
166. Rogers P.J., Richardson N.J. Why do we like drinks that contain caffeine? Trends Food Sci Technol. 4:1993;108-111.
167. Rogers P.J., Richardson N.J., Dernoncourt C. Caffeine use: is there a net benefit for mood and psychomotor performance? Neuropsychobiology. 31:1995;195-199.
168. Rush C.R., Sullivan J.T., Griffiths R.R. Intravenous caffeine in stimulant drug abusers: subjective reports and physiological effects. J Pharmacol Exp Ther. 273:1995;351-358.
169. Satoh H., Tanaka T. Comparative pharmacology between habitual and non-habitual coffee-drinkers: a practical class exercise in pharmacology. Eur J Clin Pharmacol. 52:1997;239-240.
170. Schenk S., Worley C.M., McNamara C., Valadez A. Acute and repeated exposure to caffeine: effects on reinstatement of extinguished cocaine-taking behavior in rats. Psychopharmacology. 126:1996;17-23.
171. Schiffman S.N., Jacobs O., Vanderhaeghen J.J. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem. 57:1991;1062-1067.
172. Schuster CR, Woods JH, Seevers MH. Self-administration of central stimulants by the monkey. In: Sjoqvist F, Tottie M, editors. Abuse of central stimulants. New York: Raven Press, 1969:339-347.
173. SECED. Rapport descriptif de la consommation de café, Paris, France, 1980.
174. Self D.W., Nestler E.J. Molecular mechanisms of drug reinforcement and addiction. Ann Rev Neurosci. 18:1995;463-495.
175. Shi J., Benowitz N.L., Denaro C.P., Sheiner L.B. Pharmacokinetic-pharmacodynamic modeling of caffeine: tolerance to pressor effects. Clin Pharmacol Ther. 53:1993;6-14.
176. Shuh K.J., Griffiths R.R. Caffeine reinforcement: the role of withdrawal. Psychopharmacology. 130:1997;320-326.
177. Silverman K., Evans S.M., Strain E.C., Griffiths R.R. Withdrawal syndrome after the double-blind cessation of caffeine consumption. New Engl J Med. 327:1992;1109-1114.
178. Silverman K., Griffiths R.R. Low-dose discrimination and self-reported mood effects in normal volunteers. J Exp Anal Behav. 57:1992;91-107.
179. Silverman K., Mumford G.K., Griffiths R.R. Enhancing caffeine reinforcement by behavioral requirements following drug ingestion. Psychopharmacology. 114:1994;424-432.
180. Sinton C.M., Petitjean F. The influence of chronic caffeine administration on sleep parameters in the cat. Pharmacol Biochem Behav. 32:1989;459-462.
181. Smith A.P. Caffeine dependence: an alternative view. Nature Medicine. 2:1996;494.
182. Snel J. Coffee and caffeine. Sleep and wakefulness. In: Garattini S, editor. Coffee, caffeine and health. New York: Raven Press, 1993:255-290.
183. Steigerwald E.S., Rusiniak K.W., Eckel D.L., O'Regan M.H. Aversive conditioning properties of caffeine in rats. Pharmacol Biochem Behav. 31:1989;579-584.
184. Stein E.A., Fuller S.A. Selective effects of cocaine on regional cerebral blood flow in the rat. J Pharmacol Exp Ther. 262:1992;327-334.
185. Stern K.N., Chait L.D., Johanson C.E. Reinforcing and subjective effects of caffeine in normal human volunteers. Psychopharmacology. 98:1989;81-88.
186. Strain E.C., Griffiths R.R. Caffeine dependence: fact or fiction? J Roy Soc Med. 88:1995;437-440.
187. Strain E.C., Mumford G.K., Silverman K., Griffiths R.R. Caffeine dependence syndrome. Evidence from case histories and experimental evaluations. Jama. 272:1994;1043-1048.
188. 1 opioid receptor mechanism. Science. 276:1997;2048-2050.
189. Tanda G, Loddo P, Frau R, Acquas E, Dichiara G. Effect of intravenous caffeine on limbic and cortical dopamine transmission in the rat: a microdialysis study. Proceedings of the 6th International Symposium on Adenosine and Adenine Nucleotides, Ferrara, Italy, May 19-24, 1998.
190. Tiffin P., Ashton H., Marsh R., Kamali F. Pharmacokinetic and pharmacodynamic responses to caffeine in poor and normal sleepers. Psychopharmacology. 121:1995;494-502.
191. Viani R. Composition of coffee. In: Garattini S, editor. Caffeine, coffee and health. New York: Raven Press, 1993:17-41.
192. Viani R. Caffeine consumption. Proceedings of the Caffeine Workshop, Thai FDA and ILSI Bangkok, Thailand, 1996.
193. Vitiello M., Woods S.C. Caffeine: preferential consumption by rats. Pharmacol Biochem Behav. 3:1977;147-149.
194. von Borstel R.W., Wurtman R.J., Conlay L.A. Chronic caffeine consumption potentiates the hypotensive action of circulating adenosine. Life Sci. 32:1983;1151-1158.
195. Weber J.G., Ereth M.H., Danielson D.R. Perioperative ingestion of caffeine and postoperative headache. Mayo Clin Proc. 68:1993;842-845.
196. Weber J.G., Klindworth J.T., Arnold J.J., Danielson D.R., Ereth M.K. Prophylactic intravenous administration of caffeine and recovery after ambulatory surgical procedure. Mayo Clin Proc. 72:1997;621-626.
197. World Health Organization (WHO). The ICD-10 classification of mental and behavioural disorders. World Health Organization: Geneva, 1994.
198. Worley C.M., Valadez A., Schenk S. Reinstatement of extinguished cocaine-taking behavior by cocaine and caffeine. Pharmacol Biochem Behav. 48:1994;217-221.
199. Yasuhara M., Levy G. Rapid development of functional tolerance to caffeine-induced seizures in rats. Proc Soc Exp Biol Med. 188:1988;185-190.
200. Zwyghuizen-Doorenbos A., Roehrs T., Lipschutz L., Timms V., Roth T. Effects of caffeine on alertness. Psychopharmacology. 100:1990;36-39.